Résumé
BACKGROUND Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2'antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renalcell carcinoma consisted of at least three subtypes based on molecular and phenotypic features.
langue originale | Anglais |
---|---|
Pages (de - à) | 135-145 |
Nombre de pages | 11 |
journal | New England Journal of Medicine |
Volume | 374 |
Numéro de publication | 2 |
Les DOIs | |
état | Publié - 14 janv. 2016 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: New England Journal of Medicine, Vol 374, Numéro 2, 14.01.2016, p. 135-145.
Résultats de recherche: Contribution à un journal › Article › Revue par des pairs
TY - JOUR
T1 - Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
AU - Linehan, W. Marston
AU - Spellman, Paul T.
AU - Ricketts, Christopher J.
AU - Creighton, Chad J.
AU - Fei, Suzanne S.
AU - Davis, Caleb
AU - Wheeler, David A.
AU - Murray, Bradley A.
AU - Schmidt, Laura
AU - Vocke, Cathy D.
AU - Peto, Myron
AU - Al Mamun, Abu Amar M.
AU - Shinbrot, Eve
AU - Sethi, Anurag
AU - Brooks, Samira
AU - Rathmell, W. Kimryn
AU - Brooks, Angela N.
AU - Hoadley, Katherine A.
AU - Robertson, A. Gordon
AU - Brooks, Denise
AU - Bowlby, Reanne
AU - Sadeghi, Sara
AU - Shen, Hui
AU - Weisenberger, Daniel J.
AU - Bootwalla, Moiz
AU - Baylin, Stephen B.
AU - Laird, Peter W.
AU - Cherniack, Andrew D.
AU - Saksena, Gordon
AU - Haake, Scott
AU - Li, Jun
AU - Liang, Han
AU - Lu, Yiling
AU - Mills, Gordon B.
AU - Akbani, Rehan
AU - Leiserson, Mark D.M.
AU - Raphael, Benjamin J.
AU - Anur, Pavana
AU - Bottaro, Donald
AU - Albiges, Laurence
AU - Barnabas, Nandita
AU - Choueiri, Toni K.
AU - Czerniak, Bogdan
AU - Godwin, Andrew K.
AU - Hakimi, A. Ari
AU - Ho, Thai H.
AU - Hsieh, James
AU - Ittmann, Michael
AU - Kim, William Y.
AU - Krishnan, Bhavani
AU - Merino, Maria J.
AU - Shaw, Kenna R.Mills
AU - Reuter, Victor E.
AU - Reznik, Ed
AU - Shelley, Carl S.
AU - Shuch, Brian
AU - Signoretti, Sabina
AU - Srinivasan, Ramaprasad
AU - Tamboli, Pheroze
AU - Thomas, George
AU - Tickoo, Satish
AU - Burnett, Kenneth
AU - Crain, Daniel
AU - Gardner, Johanna
AU - Lau, Kevin
AU - Mallery, David
AU - Morris, Scott
AU - Paulauskis, Joseph D.
AU - Penny, Robert J.
AU - Shelton, Candace
AU - Shelton, W. Troy
AU - Sherman, Mark
AU - Thompson, Eric
AU - Yena, Peggy
AU - Avedon, Melissa T.
AU - Bowen, Jay
AU - Gastier-Foster, Julie M.
AU - Gerken, Mark
AU - Leraas, Kristen M.
AU - Lichtenberg, Tara M.
AU - Ramirez, Nilsa C.
AU - Santos, Tracie
AU - Wise, Lisa
AU - Zmuda, Erik
AU - Demchok, John A.
AU - Felau, Ina
AU - Hutter, Carolyn M.
AU - Sheth, Margi
AU - Sofia, Heidi J.
AU - Tarnuzzer, Roy
AU - Wang, Zhining
AU - Yang, Liming
AU - Zenklusen, Jean C.
AU - Zhang, Jiashan
AU - Ayala, Brenda
AU - Baboud, Julien
AU - Chudamani, Sudha
AU - Liu, Jia
AU - Lolla, Laxmi
AU - Naresh, Rashi
AU - Pihl, Todd
AU - Sun, Qiang
AU - Wan, Yunhu
AU - Wu, Ye
AU - Ally, Adrian
AU - Balasundaram, Miruna
AU - Balu, Saianand
AU - Beroukhim, Rameen
AU - Bodenheimer, Tom
AU - Buhay, Christian
AU - Butterfield, Yaron S.N.
AU - Carlsen, Rebecca
AU - Carter, Scott L.
AU - Chao, Hsu
AU - Chuah, Eric
AU - Clarke, Amanda
AU - Covington, Kyle R.
AU - Dahdouli, Mahmoud
AU - Dewal, Ninad
AU - Dhalla, Noreen
AU - Doddapaneni, Harsha V.
AU - Drummond, Jennifer A.
AU - Gabriel, Stacey B.
AU - Gibbs, Richard A.
AU - Guin, Ranabir
AU - Hale, Walker
AU - Hawes, Alicia
AU - Hayes, D. Neil
AU - Holt, Robert A.
AU - Hoyle, Alan P.
AU - Jefferys, Stuart R.
AU - Jones, Steven J.M.
AU - Jones, Corbin D.
AU - Kalra, Divya
AU - Kovar, Christie
AU - Lewis, Lora
AU - Li, Jie
AU - Ma, Yussanne
AU - Marra, Marco A.
AU - Mayo, Michael
AU - Meng, Shaowu
AU - Meyerson, Matthew
AU - Mieczkowski, Piotr A.
AU - Moore, Richard A.
AU - Morton, Donna
AU - Mose, Lisle E.
AU - Mungall, Andrew J.
AU - Muzny, Donna
AU - Parker, Joel S.
AU - Perou, Charles M.
AU - Roach, Jeffrey
AU - Schein, Jacqueline E.
AU - Schumacher, Steven E.
AU - Shi, Yan
AU - Simons, Janae V.
AU - Sipahimalani, Payal
AU - Skelly, Tara
AU - Soloway, Matthew G.
AU - Sougnez, Carrie
AU - Tam, Angela
AU - Tan, Donghui
AU - Thiessen, Nina
AU - Veluvolu, Umadevi
AU - Wang, Min
AU - Wilkerson, Matthew D.
AU - Wong, Tina
AU - Wu, Junyuan
AU - Xi, Liu
AU - Zhou, Jane
AU - Bedford, Jason
AU - Chen, Fengju
AU - Fu, Yao
AU - Gerstein, Mark
AU - Haussler, David
AU - Kasaian, Katayoon
AU - Lai, Phillip
AU - Ling, Shiyun
AU - Radenbaugh, Amie
AU - Van Den Berg, David
AU - Weinstein, John N.
AU - Zhu, Jingchun
AU - Albert, Monique
AU - Alexopoulou, Iakovina
AU - Andersen, Jeremiah J.
AU - Auman, J. Todd
AU - Bartlett, John
AU - Bastacky, Sheldon
AU - Bergsten, Julie
AU - Blute, Michael L.
AU - Boice, Lori
AU - Bollag, Roni J.
AU - Boyd, Jeff
AU - Castle, Erik
AU - Chen, Ying Bei
AU - Cheville, John C.
AU - Curley, Erin
AU - Davies, Benjamin
AU - DeVolk, April
AU - Dhir, Rajiv
AU - Dike, Laura
AU - Eckman, John
AU - Engel, Jay
AU - Harr, Jodi
AU - Hrebinko, Ronald
AU - Huang, Mei
AU - Huelsenbeck-Dill, Lori
AU - Iacocca, Mary
AU - Jacobs, Bruce
AU - Lobis, Michael
AU - Maranchie, Jodi K.
AU - McMeekin, Scott
AU - Myers, Jerome
AU - Nelson, Joel
AU - Parfitt, Jeremy
AU - Parwani, Anil
AU - Petrelli, Nicholas
AU - Rabeno, Brenda
AU - Roy, Somak
AU - Salner, Andrew L.
AU - Slaton, Joel
AU - Stanton, Melissa
AU - Thompson, R. Houston
AU - Thorne, Leigh
AU - Tucker, Kelinda
AU - Weinberger, Paul M.
AU - Winemiller, Cynthia
AU - Zach, Leigh Anne
AU - Zuna, Rosemary
N1 - Publisher Copyright: © 2015 Massachusetts Medical Society.
PY - 2016/1/14
Y1 - 2016/1/14
N2 - BACKGROUND Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2'antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renalcell carcinoma consisted of at least three subtypes based on molecular and phenotypic features.
AB - BACKGROUND Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2'antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renalcell carcinoma consisted of at least three subtypes based on molecular and phenotypic features.
UR - http://www.scopus.com/inward/record.url?scp=84954286974&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1505917
DO - 10.1056/NEJMoa1505917
M3 - Article
C2 - 26536169
AN - SCOPUS:84954286974
SN - 0028-4793
VL - 374
SP - 135
EP - 145
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 2
ER -